Published in:
01-08-2020 | Disseminated Intravascular Coagulation | Understanding the Disease
Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19
Authors:
Bérangère S. Joly, Virginie Siguret, Agnès Veyradier
Published in:
Intensive Care Medicine
|
Issue 8/2020
Login to get access
Excerpt
Severe acute respiratory syndrome caused by coronavirus 2 (SARS-CoV-2), now classified coronavirus disease 2019 (COVID-19), was first identified in December 2019 in Wuhan, Hubei Province, China, and has now spread to all continents [
1]. About 5–10% of COVID-19 patients require intensive care unit (ICU) admission and mechanical ventilation because of progression to a severe pneumonia including parenchymal disease, massive alveolar damage and acute respiratory distress syndrome (ARDS) with radiologic patchy shadowing or ground-glass opacity [
1]. Critically ill COVID-19 patients are prone to develop not only hypoxia and excessive inflammation but frequent thrombotic manifestations like pulmonary embolisms (20–30% of cases), deep vein thrombosis (DVT), catheter-related thrombosis as well as arterial thrombosis like ischemic strokes [
2‐
5]. In addition, microvascular thrombosis, acrosyndrome and capillary leak syndrome affecting lungs, kidneys and heart, potentially complicated by multi-organ failure (MOF), are also reported [
3,
5]. The aim of this short review, which guiding thread is illustrated in the figure, is to summarize the complex mechanisms supporting the hemostasis disorders observed in critically ill COVID-19 patients. …